Hiran C Fernando1, Rodney J Landreneau2, Sumithra J Mandrekar2, Francis C Nichols2, Shauna L Hillman2, Dwight E Heron2, Bryan F Meyers2, Thomas A DiPetrillo2, David R Jones2, Sandra L Starnes2, Angelina D Tan2, Benedict D T Daly2, Joe B Putnam2. 1. Hiran C. Fernando, Boston Medical Center, Boston, MA; Rodney J. Landreneau, Dwight E. Heron, and Benedict D.T. Daly, University of Pittsburgh, Pittsburgh, PA; Sumithra J. Mandrekar, Francis C. Nichols, Shauna L. Hillman, and Angelina D. Tan, Mayo Clinic, Rochester, MN; Bryan F. Meyers, Washington University of St Louis, St Louis, MO; Thomas A. DiPetrillo, Rhode Island Hospital, Providence, RI; David R. Jones, University of Virginia, Charlottesville, VA; Sandra L. Starnes, University of Cincinnati, Cincinnati, OH; and Joe B. Putnam Jr, Vanderbilt University Medical Center, Nashville, TN. Hiran.Fernando@bmc.org. 2. Hiran C. Fernando, Boston Medical Center, Boston, MA; Rodney J. Landreneau, Dwight E. Heron, and Benedict D.T. Daly, University of Pittsburgh, Pittsburgh, PA; Sumithra J. Mandrekar, Francis C. Nichols, Shauna L. Hillman, and Angelina D. Tan, Mayo Clinic, Rochester, MN; Bryan F. Meyers, Washington University of St Louis, St Louis, MO; Thomas A. DiPetrillo, Rhode Island Hospital, Providence, RI; David R. Jones, University of Virginia, Charlottesville, VA; Sandra L. Starnes, University of Cincinnati, Cincinnati, OH; and Joe B. Putnam Jr, Vanderbilt University Medical Center, Nashville, TN.
Abstract
PURPOSE: A major concern with sublobar resection (SR) for non-small-cell lung cancer (NSCLC) is high local recurrence (LR). Adjuvant brachytherapy may reduce LR This multicenter randomized trial compares SR to SR with brachytherapy (SRB). PATIENTS AND METHODS: High-risk operable patients with NSCLC ≤ 3 cm were randomly assigned to SR or SRB. The primary end point was time to LR, where LR included recurrence at the staple line (local progression), in the primary tumor lobe away from the staple line, and in ipsilateral hilar nodes. The trial was designed to have a 90% power to detect a hazard ratio (HR) of 0.315 in favor of SRB, using a one-sided type I error rate of 0.05 with a sample size of 100 eligible patients in each arm. RESULTS:Two hundred twenty-four patients were randomly assigned; 222 patients were evaluable for intent-to-treat analysis. Median age was 71 years (range, 49 to 87 years). No differences were found in baseline characteristics. Median follow-up time was 4.38 years (range, 0.04 to 5.59 years). There was no difference in time to LR (HR, 1.01; 95% CI, 0.51 to 1.98; log-rank P = .98) or in the types of LR. Local progression occurred in only 17 (7.7%) of 222 patients. In patients with potentially compromised margins (margin < 1 cm, margin-to-tumor ratio < 1, positive staple line cytology, wedge resection, nodule size > 2.0 cm), SRB did not reduce LR, although trends favored the SRB arm. This was most marked in 14 patients with positive staple line cytology (HR, 0.22; P = .24). Three-year overall survival rates were similar for patients in the SR (71%) and SRB (71%) arms (P = .97). CONCLUSION:Brachytherapy did not reduce LR after SR. This finding may have been related to closer attention to parenchymal margins by surgeons participating in this study.
RCT Entities:
PURPOSE: A major concern with sublobar resection (SR) for non-small-cell lung cancer (NSCLC) is high local recurrence (LR). Adjuvant brachytherapy may reduce LR This multicenter randomized trial compares SR to SR with brachytherapy (SRB). PATIENTS AND METHODS: High-risk operable patients with NSCLC ≤ 3 cm were randomly assigned to SR or SRB. The primary end point was time to LR, where LR included recurrence at the staple line (local progression), in the primary tumor lobe away from the staple line, and in ipsilateral hilar nodes. The trial was designed to have a 90% power to detect a hazard ratio (HR) of 0.315 in favor of SRB, using a one-sided type I error rate of 0.05 with a sample size of 100 eligible patients in each arm. RESULTS: Two hundred twenty-four patients were randomly assigned; 222 patients were evaluable for intent-to-treat analysis. Median age was 71 years (range, 49 to 87 years). No differences were found in baseline characteristics. Median follow-up time was 4.38 years (range, 0.04 to 5.59 years). There was no difference in time to LR (HR, 1.01; 95% CI, 0.51 to 1.98; log-rank P = .98) or in the types of LR. Local progression occurred in only 17 (7.7%) of 222 patients. In patients with potentially compromised margins (margin < 1 cm, margin-to-tumor ratio < 1, positive staple line cytology, wedge resection, nodule size > 2.0 cm), SRB did not reduce LR, although trends favored the SRB arm. This was most marked in 14 patients with positive staple line cytology (HR, 0.22; P = .24). Three-year overall survival rates were similar for patients in the SR (71%) and SRB (71%) arms (P = .97). CONCLUSION: Brachytherapy did not reduce LR after SR. This finding may have been related to closer attention to parenchymal margins by surgeons participating in this study.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Matthew J Schuchert; Brian L Pettiford; Samuel Keeley; Thomas A D'Amato; Arman Kilic; John Close; Arjun Pennathur; Ricardo Santos; Hiran C Fernando; James R Landreneau; James D Luketich; Rodney J Landreneau Journal: Ann Thorac Surg Date: 2007-09 Impact factor: 4.330
Authors: Hiran C Fernando; Rodney J Landreneau; Sumithra J Mandrekar; Shauna L Hillman; Francis C Nichols; Bryan Meyers; Thomas A DiPetrillo; Dwight E Heron; David R Jones; Benedict D T Daly; Sandra L Starnes; Angelina Tan; Joe B Putnam Journal: J Thorac Cardiovasc Surg Date: 2011-08-26 Impact factor: 5.209
Authors: Winnie Lee; Benedict D T Daly; Thomas A DiPetrillo; Donna M Morelli; Andrew C Neuschatz; Jody Morr; Mark J Rivard Journal: Ann Thorac Surg Date: 2003-01 Impact factor: 4.330
Authors: Damian E Dupuy; Thomas DiPetrillo; Sachin Gandhi; Neal Ready; Thomas Ng; Walter Donat; William W Mayo-Smith Journal: Chest Date: 2006-03 Impact factor: 9.410
Authors: Inga S Grills; Victor S Mangona; Robert Welsh; Gary Chmielewski; Erika McInerney; Shannon Martin; Jennifer Wloch; Hong Ye; Larry L Kestin Journal: J Clin Oncol Date: 2010-01-11 Impact factor: 44.544
Authors: Amgad El-Sherif; Hiran C Fernando; Ricardo Santos; Brian Pettiford; James D Luketich; John M Close; Rodney J Landreneau Journal: Ann Surg Oncol Date: 2007-05-16 Impact factor: 5.344
Authors: Michael S Kent; Sumithra J Mandrekar; Rodney Landreneau; Francis Nichols; Thomas A DiPetrillo; Bryan Meyers; Dwight E Heron; David R Jones; Angelina D Tan; Sandra Starnes; Joe B Putnam; Hiran C Fernando Journal: Ann Thorac Surg Date: 2016-04-19 Impact factor: 4.330
Authors: Michael S Kent; Sumithra J Mandrekar; Rodney Landreneau; Francis Nichols; Nathan R Foster; Thomas A DiPetrillo; Bryan Meyers; Dwight E Heron; David R Jones; Angelina D Tan; Sandra Starnes; Joe B Putnam; Hiran C Fernando Journal: Ann Thorac Surg Date: 2016-04-19 Impact factor: 4.330
Authors: Manuel Valdivieso; Benjamin W Corn; Janet E Dancey; D Lawrence Wickerham; L Elise Horvath; Edith A Perez; Alison Urton; Walter M Cronin; Erica Field; Evonne Lackey; Charles D Blanke Journal: Semin Oncol Date: 2015-07-10 Impact factor: 4.929
Authors: Waddah B Al-Refaie; Paul A Decker; Karla V Ballman; Peter W T Pisters; Mitchell C Posner; Kelly K Hunt; Bryan Meyers; Armin D Weinberg; Heidi Nelson; Lisa Newman; Angelina Tan; Jennifer G Le-Rademacher; Arti Hurria; Aminah Jatoi Journal: Ann Surg Oncol Date: 2019-10-11 Impact factor: 5.344
Authors: David A Mahvi; Rong Liu; Mark W Grinstaff; Yolonda L Colson; Chandrajit P Raut Journal: CA Cancer J Clin Date: 2018-10-17 Impact factor: 508.702